Mind Medicine (MindMed) (MNMD) Competitors $7.16 +0.65 (+9.98%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends MNMD vs. APGE, TARS, IOVA, AMPH, IRON, BLTE, IBRX, WVE, ARQT, and INDVShould you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include Apogee Therapeutics (APGE), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Amphastar Pharmaceuticals (AMPH), Disc Medicine (IRON), Belite Bio (BLTE), ImmunityBio (IBRX), Wave Life Sciences (WVE), Arcutis Biotherapeutics (ARQT), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry. Mind Medicine (MindMed) vs. Apogee Therapeutics Tarsus Pharmaceuticals Iovance Biotherapeutics Amphastar Pharmaceuticals Disc Medicine Belite Bio ImmunityBio Wave Life Sciences Arcutis Biotherapeutics Indivior Mind Medicine (MindMed) (NASDAQ:MNMD) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, community ranking, risk, media sentiment and profitability. Is MNMD or APGE more profitable? Apogee Therapeutics' return on equity of -21.81% beat Mind Medicine (MindMed)'s return on equity.Company Net Margins Return on Equity Return on Assets Mind Medicine (MindMed)N/A -47.56% -35.55% Apogee Therapeutics N/A -21.81%-20.94% Does the media refer more to MNMD or APGE? In the previous week, Mind Medicine (MindMed) and Mind Medicine (MindMed) both had 3 articles in the media. Mind Medicine (MindMed)'s average media sentiment score of 0.85 beat Apogee Therapeutics' score of 0.46 indicating that Mind Medicine (MindMed) is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mind Medicine (MindMed) 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in MNMD or APGE? Mind Medicine (MindMed) received 27 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 92.73% of users gave Mind Medicine (MindMed) an outperform vote. CompanyUnderperformOutperformMind Medicine (MindMed)Outperform Votes5192.73% Underperform Votes47.27%Apogee TherapeuticsOutperform Votes24100.00% Underperform VotesNo Votes Do institutionals and insiders believe in MNMD or APGE? 27.9% of Mind Medicine (MindMed) shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 2.3% of Mind Medicine (MindMed) shares are held by company insiders. Comparatively, 36.1% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility & risk, MNMD or APGE? Mind Medicine (MindMed) has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 2.26, meaning that its stock price is 126% more volatile than the S&P 500. Do analysts recommend MNMD or APGE? Mind Medicine (MindMed) presently has a consensus target price of $26.75, suggesting a potential upside of 273.60%. Apogee Therapeutics has a consensus target price of $89.71, suggesting a potential upside of 142.08%. Given Mind Medicine (MindMed)'s stronger consensus rating and higher possible upside, analysts plainly believe Mind Medicine (MindMed) is more favorable than Apogee Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mind Medicine (MindMed) 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.25Apogee Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, MNMD or APGE? Apogee Therapeutics is trading at a lower price-to-earnings ratio than Mind Medicine (MindMed), indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMind Medicine (MindMed)N/AN/A-$95.73M-$2.26-3.17Apogee TherapeuticsN/AN/A-$83.99M-$2.42-15.31 SummaryMind Medicine (MindMed) beats Apogee Therapeutics on 8 of the 14 factors compared between the two stocks. Get Mind Medicine (MindMed) News Delivered to You Automatically Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNMD vs. The Competition Export to ExcelMetricMind Medicine (MindMed)Medicinals & botanicals IndustryMedical SectorNASDAQ ExchangeMarket Cap$508.19M$1.19B$5.24B$9.00BDividend YieldN/AN/A5.13%4.03%P/E RatioN/A23.4665.3814.27Price / SalesN/A5.721,272.1186.92Price / CashN/A9.9643.8235.97Price / Book3.772.045.324.80Net Income-$95.73M-$53.10M$122.68M$224.91M7 Day Performance3.32%-1.14%-0.21%1.47%1 Month Performance-0.83%-1.05%3.72%4.66%1 Year Performance97.25%-6.03%27.18%20.83% Mind Medicine (MindMed) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNMDMind Medicine (MindMed)2.2986 of 5 stars$7.16+10.0%$26.75+273.6%+88.9%$508.19MN/A0.0040High Trading VolumeAPGEApogee Therapeutics2.5317 of 5 stars$40.30-1.8%$89.71+122.6%+17.3%$1.81BN/A-16.6591TARSTarsus Pharmaceuticals1.812 of 5 stars$47.41-10.0%$54.20+14.3%+98.6%$1.81B$129.62M-12.4450News CoveragePositive NewsGap DownIOVAIovance Biotherapeutics4.1591 of 5 stars$5.92-7.5%$23.00+288.5%-26.5%$1.80B$90.86M-3.97500News CoverageGap UpAMPHAmphastar Pharmaceuticals4.5112 of 5 stars$37.51+3.2%$60.33+60.8%-36.4%$1.80B$723.55M12.501,620Short Interest ↑IRONDisc Medicine2.5686 of 5 stars$58.32-1.6%$87.50+50.0%-10.4%$1.74BN/A-14.6530Short Interest ↑News CoverageBLTEBelite Bio3.298 of 5 stars$55.90+0.8%$89.00+59.2%+21.8%$1.73BN/A-50.3610Short Interest ↓News CoveragePositive NewsGap DownIBRXImmunityBio2.3566 of 5 stars$2.46+1.7%$13.58+452.2%-19.5%$1.71B$7.33M-2.67590Analyst ForecastOptions VolumeNews CoverageGap UpWVEWave Life Sciences4.7692 of 5 stars$11.04-4.3%$22.22+101.3%+133.3%$1.68B$53.61M-9.95240ARQTArcutis Biotherapeutics2.4194 of 5 stars$13.70-0.8%$16.60+21.2%+279.6%$1.60B$138.71M-7.65150Short Interest ↓Gap UpINDVIndivior2.1012 of 5 stars$11.59-2.2%$16.00+38.1%-24.8%$1.60B$1.18B-289.681,164Short Interest ↑News Coverage Related Companies and Tools Related Companies APGE Alternatives TARS Alternatives IOVA Alternatives AMPH Alternatives IRON Alternatives BLTE Alternatives IBRX Alternatives WVE Alternatives ARQT Alternatives INDV Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MNMD) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mind Medicine (MindMed) Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mind Medicine (MindMed) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
